Advertisement

European Journal of Clinical Pharmacology

, Volume 32, Issue 4, pp 351–355 | Cite as

Factors affecting the pharmacokinetics of nifedipine

  • A. G. renwick
  • J. Le Vie
  • V. F. Challenor
  • D. G. Waller
  • B. Gruchy
  • C. F. George
Originals

Summary

The plasma pharmacokinetics of nifedipine and the formation of its metabolites have been studied in volunteers under conditions which would affect the activity of the cytochrome P-450 system.

The pharmacokinetics of a 10-mg capsule of nifedipine were not significantly different between smokers and non-smokers of similar age.

After pretreatment with cimetidine, which inhibits the activity of cytochrome P-450, the peak plasma concentration and area under the plasma-time concentration curve for nifedipine were increased by a mean 84%. In contrast, pre-treatment with ranitidine which has little effect on cytochrome P-450, did not significantly alter nifedipine pharmacokinetics.

Smoking does not contribute significantly to the variability in nifedipine pharmacokinetics. However, the interaction between nifedipine and cimetidine, but not ranitidine, may be of clinical importance.

Key words

nifedipine cimetidine pharmacokinetics drug interaction 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baarnhielm C, Skanberg I, Borg KO (1984) Cytochrome P-450-dependent oxidation of felodipine — a 1,4-dihydropyridine — to the corresponding pyridine. Xenobiotica 14: 719–726Google Scholar
  2. Baarnhielm C, Hansson G (1986) Oxidation of 1-4-dihydropyridines by prostaglandin synthase and the peroxidic function of cytochrome P-450. Biochem Pharmacol 35: 1419–1425Google Scholar
  3. Banzet O, Colin JN, Thibonnier M, Singlas E, Alexandre JM, Corvol P (1983) Acute anti-hypertensive effect and pharmacokinetics of a tablet preparation of nifedipine. Eur J Clin Pharmacol 24: 145–150Google Scholar
  4. Bell JA, Gower AJ, Martin LE, Mills ENC, Smith WP (1981) Interaction of H2-receptor antagonists with drug-metabolising enzymes. Biochem Soc Trans 9: 113–114Google Scholar
  5. Breen KJ, Bury R, Desmond PV, Mashford ML, Morphett B, Westwood B, Shaw RG (1982) Effects of cimetidine and ranitidine on hepatic drug metabolism. Clin Pharmacol Ther 31: 297–300Google Scholar
  6. Challenor VF, Waller DG, Gruchy BS, Renwick AG, George CF (1987) Food and nifedipine pharmacokinetics. Br J Clin Pharmacol 23: 248–249Google Scholar
  7. Conney AH (1967) Pharmacological implications of microsomal enzyme induction. Pharmacol Rev 19: 317–366Google Scholar
  8. Deanfield J, Wright C, Krikler S, Ribiero P, Fox K (1984) Cigarette smoking and the treatment of angina with propranolol, atenolol and nifedipine. New Engl J Med 310: 951–954Google Scholar
  9. Feely J, Guy E (1982) Ranitidine also reduces liver blood flow. Lancet 1: 169Google Scholar
  10. Feely J, Wilkinson GR, Wood AJJ (1981) Reduction of liver blood flow and propranolol metabolism by cimetidine. N Engl J Med 304: 692–695Google Scholar
  11. Foster TS, Hamann SR, Richards VR, Bryant PJ, Graves DA, McAllister RG (1983) Nifedipine kinetics and bioavailability after a single oral dose in normal subjects. J Clin Pharmacol 23: 161–170Google Scholar
  12. Gibaldi M, Perrier D (1982) Pharmacokinetics (2nd edn revised and expanded). Marcel Dekker, New YorkGoogle Scholar
  13. Hamann SR, Tan TG, Kaltenborn KE, Brower KLR, Blouin RA, Chang SL, Vore M, McAllister RG (1985) Effects of phenobarbital and SKF-525A on in vitro hepatic metabolism of verapamil and nifedipine. Pharmacology 30: 121–128Google Scholar
  14. Horster FA, Duhm B, Maul W, Medenwald H, Patzschke K, Wegner LA (1972) Clinical investigations on the pharmacokinetics of radioactively marked 4-(2′-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine3,5-dicarboxylic acid dimethyl ester. Arzneimittelforsch (Drug Res) 22: 330–334Google Scholar
  15. Kirch W, Janisch HD, Heidemann H, Ramsch K, Ohnhaus E (1983) Einfluß von Cimetidin und Ranitidin auf Pharmacokinetik und antihypertensiven Effekt von Nifedipin. Dtsch Med Wochenschr 108: 1757–1761Google Scholar
  16. Kirch W, Hoensch H, Janisch HD (1984) Interactions and non-interactions with ranitidine. Clin Pharmacokinet 9: 493–510Google Scholar
  17. Kleinbloesem CH, Van Harten J, Van Brummelen P, Breiner DD (1984) Liquid chromatographic determination of nifedipine in plasma and its main metabolite in urine. J Chromatogr 308: 209–216Google Scholar
  18. Miller RR (1977) Effects of smoking on drug action. Clin Pharmacol Ther 22: 749–756Google Scholar
  19. Piper DW (1983) Drugs for the prevention of peptic ulcer recurrence. Drugs 26: 439–453Google Scholar
  20. Raemsch KD, Sommer J (1983) Pharmacokinetics and metabolism of nifedipine. Hypertension 5: II18-II24Google Scholar
  21. Rendic S, Akbic-Kolbah T, Kajfez F, Ruf HH (1982) Interaction of ranitidine with liver microsomes. Xenobiotica 12: 9–17Google Scholar
  22. Rendic S, Sunjic V, Toso R, Kajfez F, Ruf HH (1979) Interaction of cimetidine with liver microsomes. Xenobiotica 9: 555–564Google Scholar
  23. Somogyi A, Gugler R (1982) Drug interactions with cimetidine. Clin Pharmacokinet 7: 23–41Google Scholar
  24. Thibonnier M, Bonnet F, Corvol P (1980) Antihypertensive effect of fractionated sublingual administration of nifedipine in moderate essential hypertension. Eur J Clin Pharmacol 17: 161–164Google Scholar
  25. Vestal RE, Wood AJJ (1980) Influence of age and smoking on drug kinetics in man. Studies using model compounds. Clin Pharmacokinet 5: 309–319Google Scholar
  26. Waller DG, Renwick AG, Gruchy BS, George CF (1984) The first pass metabolism of nifedipine in man. Br J Clin Pharmacol 18: 951–954Google Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • A. G. renwick
    • 1
  • J. Le Vie
    • 1
  • V. F. Challenor
    • 1
  • D. G. Waller
    • 1
  • B. Gruchy
    • 1
  • C. F. George
    • 1
  1. 1.Clinical Pharmacology Group, Medical and Biological Sciences BuildingUniversity of SouthamptonSouthamptonU.K.

Personalised recommendations